Can a drug plus nerve training restore leg movement after paralysis?

NCT ID NCT05447676

Completed Disease control Sponsor: Shirley Ryan AbilityLab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed early-phase trial tested whether the drug 4-AP (dalfampridine), combined with special nerve stimulation and leg exercises, could improve muscle strength and control in people with spinal cord injury. 26 adults with injuries at or above the lower back took part. The goal was to see if this combination could boost the brain's ability to send signals past the injury site.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalfampridine (4-AP)
What this could lead to: If successful, this approach could point toward a way to improve leg movement and strength in people with spinal cord injury.
What could go wrong: This is a very early, small trial (26 people) testing a combination of therapies, so results may not be strong or widely applicable. The drug can have side effects like dizziness or urinary tract infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL CORD INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPINAL CORD INJURY

Contacts and locations

Locations

Shirley Ryan Abilitylab

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.